home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2606.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
29 lines
Document 2606
DOCN M94A2606
TI Is hepatitis B vaccine effective in HIV-positives? Changes in hepatitis
markers during the AIDS epidemic.
DT 9412
AU Ifft FN; Greater Phila. Health Action, PA 19147.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):266 (abstract no. PB0493). Unique
Identifier : AIDSLINE ICA10/94369969
AB METHOD: Retrospective analysis of HIV+ patients' presenting Hepatits
serologies: 1983-93, and prospective evaluation of vaccine in subset of
Hep B marker negatives. RESULTS: Prior to 1988, 74% of all newly
presenting HIV+ patients had Hep-sAG (14%) or sAB (60%); 8% had core-AB
only; 11% had no markers. This pattern has changed progressively with
time: 1993 figures are 15%; 18%; 21.5%: and 35.4% respectively. No
patients with initial CD-4 less than 500 responded to vaccine.
CONCLUSION: Serologic response to Hep BsAg is compromised by
pre-existing HIV infection; vaccination may not be cost-effective. This
issue deserves further investigation.
DE Cost-Benefit Analysis *Disease Outbreaks Hepatitis
B/*IMMUNOLOGY/PREVENTION & CONTROL Hepatitis B Antibodies/BLOOD
Hepatitis B Core Antigens/BLOOD Hepatitis B Surface Antigens/BLOOD
Hepatitis B Vaccines/ADMINISTRATION & DOSAGE/ECONOMICS/ *IMMUNOLOGY
Human HIV Seropositivity/*IMMUNOLOGY Retrospective Studies MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).